Nabriva halts R&D, lays off 40% of staff in commercial-focused pivot for survival

Irish biotech Nabriva Therapeutics has responded to the tough financial climate by putting all its chips on the approved bacterial skin medicine Sivextro, meaning its R&D projects and 40% of staff are now surplus to requirements.